

899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002

August 6, 2020

9:00 am

OPEN SESSION AGENDA
(VIA ZOOM MEETING DUE TO THE COVID-19 PUBLIC HEALTH EMERGENCY)

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

Open Session Agenda

Quorum:

| | | |
|--|--|--------------------|
| Introduction: | | |
| o8o6-O-01 | <u>Approval of the Open Session Meeting Minutes</u> (a) June 4, 2020 (b) July 2, 2020 | |
| <u>Consent Agenda</u> | None | |
| <u>Chairperson Report</u> | Interprofessional Workgroup MPJE Item Writer | Dr. Tamara McCants |
| <u>Executive Director Report</u> | <u>Licensing Report</u> <ul style="list-style-type: none"> ▪ Statistical Report on pharmacy professionals in the District of Columbia ▪ Prescription Monitoring Program Update ▪ Opioid Strategic Plan ▪ CE Programs ▪ Pharmacist COVID-19 Testing Guidance Document ▪ Emergency Regulations Pharmacist COVID-19 Testing (Document Attached) ▪ NCPA Letter Pharmacist COVID-19 Testing (Document Attached) | Dr. Shauna White |
| <u>Assistant General Counsel Report</u> | | Ms. Carla Williams |
| o8o6-O-02 | <u>Status Update on the Rulemaking Adding Continuing Education Requirements in Public Health Priorities</u> | |
| o8o6-O-03 | <u>Draft Collaborative Practice Agreement Regulations with Nurse Practitioners</u> (a) Chapter 104 Collaborative Practice Agreements Between Nurse-Practitioners and Pharmacists | |
| <u>Subcommittee Reports</u> | | |
| | <u>Legislative and Regulatory Subcommittee Report</u> | Mr. Alan Friedman |
| o8o6-O-04 | <u>CPA – Board of Medicine Update</u> | |

| | | |
|---|---|--------------------|
| o8o6-O-05 | <u>Communications Subcommittee Report</u> | Dr. Ashlee Bow |
| <u>Matters for Consideration</u> | | |
| o8o6-O-06 | <u>DC Board of Pharmacy Bylaws</u> (a) Bylaws | |
| o8o6-O-07 | <u>CE Audit Fine for Pharmacy Technicians</u> | |
| <u>Intern Presentation</u> | | |
| o8o6-O-08 | <u>Intern Presentation Summary of NABP E-News</u> | Olyad Begna |
| NABP E-Newsletter | <p><u>July 29, 2020</u></p> <p>FDA Recommends Health Care Providers Discuss Naloxone With Patients Receiving Opioids or Treatment for OUD</p> <p>USP to Host Virtual Public Open Forum Regarding BUDs in Chapters <795> and <797></p> <p>HHS Announces National COVID-19 Testing Implementation Forum</p> <p>CDC Data Analysis Surveys Opioid Use by Pregnant Women</p> <p><u>July 22, 2020</u></p> <p>Opioid-Related Deaths in Cook County, IL, Rise Due to Need for COVID-19 Prevention Measures</p> <p>FIP Releases New COVID-19 Guidance for Pharmacists</p> <p>FDA Adds Dexamethasone Sodium Phosphate to List of Drugs for Temporary Compounding</p> <p>SAMHSA’s Health Privacy Rule 42 CFR Part 2 Revised to Better Integrate, Coordinate Care for Substance Use Disorders</p> <p>NABP Offers Opportunities to Earn Home Study CPE</p> <p><u>July 17, 2020</u></p> <p>HHS Secures More Than 500,000 Courses of Remdesivir for US Hospitals to Treat COVID-19 Patients</p> <p>Reminder: Four-Part Webinar Series on Confluence of the COVID-19 Pandemic and the Opioid Epidemic Begins July 20</p> | Dr. Tamara McCants |

| | | |
|---|---|--|
| | <p>New HHS Web Page Shares COVID-19 Testing Plans for Each State, Jurisdiction</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/.</p> | |
| <u>Public Comments</u> | | |
| Motion to Adjourn the Open Session | <p>"Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." (Roll Call Vote)</p> | |

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at _:

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.